Form Approved
OMB No. 0925-0657
Exp. Date 07/31/2018
(to be updated upon OMB approval)

# Attachment A DERT Extramural Grantee Data Collection Survey

Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch; 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0657). Do not return the completed form to this address.

## **DEMOGRAPHICS AND BACKGROUND INFORMATION**

Grant Number:	
How did you learn about this funding opportunity?  NIEHS Website Grants.gov Social Media (Twitter, Linked In, etc.) Colleague/Word of Mouth Conference/Webinar University-based Resource (Tech Transfer Office) Federal Register	
What is your age?  □ <30 □ 30-39 □ 40-49 □ 50-59 □ 60+	
What degrees do you hold? (Please check all that ap AB, BA, BS, BSc AB, MA, MS, MHS, MPH, MPA, MED, MSIH PhD, Sc.D, DSc MD Other clinical degree (e.g. DO, DDS, MBBS, RN) Other please specify None	oply)
In what year did you receive your highest degree?	(drop down menu
What is your current position?	
How long have you held that position?	ears Months

In what type of research do you engage? (Please check all that apply)

Indicate whether	Basic	Applied			
you research in a			Biochemistry		
specific area was			Biophysics		
basic or applied			Botany		
(Please check all			Cellular biology		
that apply)			Ecology		
			Environmental Sciences		
			Epidemiology/Human or Cohort studies (new association between biological, social, and/or behavioral states determined)		
			Epigenetics		
			Genetics (GWAS)		
			Immunology		
			Medicine		
			Microbiology		
			Molecular biology		
			Neuroscience		
			Physiology		
			Toxicology		
			Other please specify		
If your research		Clinical Re	esearch		
was appliedWhat			alth Research		
types of applied		Health Services Research			
research? (Please		Intervention Research			
check all that apply)		Program or Policy Research			
		Technology Innovation			
		Translational Research			
		Other ple	ease specify		

## **FUNDING**

Please indicate which sources of selected science portfolio-related funding you have had during your career to date.

0	Please check all sources of		Please indicate which			
S	selected scie	nce portfolio -	funding source was the			
r	<b>related</b> fundi	ng	primary funder for this			
(	(Please select	t all that apply)	research.			
	Career	Last 10 years	Career	Last 10 years		
HS						
LBI		<u> </u>		<u> </u>		
ID		<u> </u>				
HD						
er NIH						
RQ						
1						
1						
D						
:						
er US government (not						
ed above)						
ndations						
ustry						
versity discretionary/						
t-up funds						
al, state or regional						
ernment						
er, specify						
ner NIH C RQ A A D E Her US government (not led above) Indations Sustry Versity discretionary/ Int-up funds Intal State or regional leernment						

For your NIH-funded selected science portfolio research, please indicate which types of
funding you have received. (Please check all that apply).
☐ Research (e.g., R01, R03, R21)
☐ Program/Center (e.g., M, P and U awards)
☐ Career Development Individual (e.g., K awards; R23, R29)
☐ Fellowships (e.g., F awards)
☐ Institutional Training (e.g., T32)
☐ Technology Development (e.g., SBIR, STTR; R41-44, N43-44, U43-44)
☐ Other funding type (specify):

Please describe if and how you have used NIEHS funds to leverage other resources
including monetary and non-monetary
support

#### **OUTPUTS**

# Research Outputs

Please indicate which of the following research outputs you have produced as part of this project and provide a brief description:

Research Output	Check all that apply:	Provide a brief description.
Animal Models	Animal model developed	
Biological Materials	Biological material or application identified or developed as a result of the research study	
Clinical Products	<ul> <li>Medication, drug compounds, clinical devices (includes development and testing of these products)</li> </ul>	
Databases,	Database resulting from the research study	
Software, Algorithms	Software resulting from the research study	
Augoritimis	Algorithm resulting from the research study	
License Agreements	License agreement executed for intellectual property generated by the research study.	
Measurement Instruments, Assays & Methods	Measurement instrument developed by the research study	
Research Data (public or restricted)	Research data generated by the research study	
Economic Outcomes	Research study findings result in a cost-effective intervention for a disease, condition, or disorder	
	Research study findings result in enhancement of existing resources and expertise	
	<ul> <li>Research study findings result in increased performance, quality, and consistency in the delivery of health care services</li> </ul>	
Health Care Outcomes	<ul> <li>Research study findings result in clinically effective approach in the management and treatment of a disease, disorder or condition</li> </ul>	
Quality of Life	<ul> <li>Research study findings leads to enhancement of well- being among community members</li> </ul>	

# **Knowledge Transfer Outputs**

Please indicate which of the following knowledge transfer outputs you have produced as part of this project and provide a brief description:

Knowledge Transfer Output	Check all that apply:	Provide a brief description.
Alternative/ Informal Dissemination	<ul> <li>Research study is referred to or cited in a blog, tweet, wiki or other alternative mode of dissemination.</li> <li>Research study is cited in a presentation,</li> </ul>	
Biological Materials	<ul> <li>speech or teaching materials.</li> <li>Subsequent use of a particular biological material or application of the material generated by the research study in a bench study (basic science) or clinical trial study.</li> </ul>	
	<ul> <li>Preclinical data generated in support of investigational new drug (IND) application or to the receipt of an IND.</li> <li>Clinical data generated in support of marketing</li> </ul>	
	a biological material (Biologic License Application) generated by the research study.	
Clinical Guidelines	<ul> <li>The clinical guideline refers to the research study or recommends the study for background readings.</li> </ul>	
Curriculum Guidelines	<ul> <li>The curriculum guideline refers to the research study or recommends the study for background readings.</li> </ul>	
License Agreements	<ul> <li>License agreement granted for use of intellectual property generated by the research study.</li> </ul>	
Mass Media	<ul> <li>Mass media publication refers to the research study.</li> </ul>	
Material Transfer Agreements (MTA)	<ul> <li>MTA executed for transfer of tangible property generated by the research study.</li> </ul>	
Medical Devices	Clinical trial study testing of a medical device generated by the research study.	
	<ul> <li>Clinical data generated in support of marketing a medical device (510(k); Investigational Device Exemption, IDE; or Premarket Approval, PMA) generated by the research study.</li> </ul>	
Meta-Analyses	Research study cited in a meta-analysis.	

Knowledge Transfer Output	Check all that apply:	Provide a brief description.
Pharmaceutical Preparations	<ul> <li>Subsequent use of a drug generated by the research study in a bench study (basic science/preclinical) or clinical trial study, including application and/or receipt of an Investigational New Drug Application (IND) from the FDA.</li> </ul>	
	<ul> <li>Clinical data generated in support of marketing a drug (Drug Application, NDA; Abbreviated New Drug Application, ANDA; or 505(b)(2)) generated by the research study.</li> </ul>	
Ancillary Research Studies	<ul> <li>Ancillary research study generated as a result of the research study.</li> </ul>	
New Research Studies	New research study generated as a result of the research study.	
Subject Headings/ Thesauri	<ul> <li>New subject heading or thesauri term or phrase resulting or related to the research study is applied.</li> </ul>	

## **Career Development Outputs**

Career Development Output	Check all that apply:	Provide a brief description.
University Leadership Positions	<ul> <li>Serve as Center Director, Department Chair, or other university leadership position</li> </ul>	
Organizational/ Conference Leadership Position	<ul> <li>Serve as conference chair, organizational leader (Society of Toxicology, International Society of Environmental Epidemiology, etc.)</li> </ul>	
Nominated for Membership in Prestigious Organization	<ul> <li>Nominated for membership in prestigious organization such as Institute of Medicine, American Association for Advancement of Science, etc.</li> </ul>	
Employment Promotion	<ul> <li>Received promotion to higher level of employment, such as next level of professor, or scientist</li> </ul>	
Obtained Tenure Status	<ul> <li>Obtained tenure status for research or teaching position</li> </ul>	
Trained or Mentored Students	Served as a mentor or trained students in the field of selected science portfolio	
Additional Training or Certification Received	Obtained additional training (K awards) or certifications within the field of environmental health science	

**Training/Certifications Outputs** 

Career Development Output	Check all that apply:	Provide additional information.
Teaching	Taught courses in the area of the selected science portfolio	Number of courses taught: Number of students taught: Description of courses taught:
New Investigators Recruited to NIEHS	<ul> <li>Recruited new investigators to submit applications to NIEHS</li> </ul>	Number of new investigators recruited (new investigator has not previously had a substantial NIH award such as an R01, P30, etc.):
Young Investigators Recruited to NIEHS	<ul> <li>Recruited early stage investigators to submit applications to NIEHS</li> </ul>	Number of early stage investigators recruited (early stage investigators are within 10 years of their terminal degree or medical residency):

Describe the approaches you used to include/advance young investigators.

Which of these approaches was most effective? Describe why.

Describe the barriers you face to training the next generation of NIEHS scientists.

#### **Dissemination Outputs**

Please indicate which of the following mechanisms you have used to disseminate related knowledge and products stemming from your research. (*Please check all that apply*).

Published in peer-reviewed <b>journals</b>
Presented at scientific conferences
Participated in grantee meetings
Developed and disseminated curricula
Developed and disseminated interventions
Participated in the development of clinical guidelines
Developed and disseminated research tools and methods
Participated in workshops or trainings disseminating your research
Provided scientific testimony and briefings to legislators
Developed and published websites
Presented research in <b>community forums</b>
Developed fact sheets and pamphlets
Provided information for press releases
Other, please specify:

As part of your research, you may have had the opportunity to engage with different types of individuals and groups. Please indicate what the nature of your personal engagement has been with each of the following groups. (*Please check all that apply*)

<u>Group</u>	Share information	Conduct joint projects or artivities	Serve on boards or advisory panels	Provide formal testimony	Serve as employee or consultant	No interaction
Other researchers University administration / program directors Local, regional or national health officials Environmental regulators Food and drug regulators Legislators and staffers Business and industry representatives Housing and urban development agencies Advocacy groups Community groups Other:						
Commercialization Outputs						
We are interested in whether your selected sci regardless of funding source, has led to the de						
Have you <b>applied</b> for one or more patents? ☐ Yes ☐ No						
[IF YES] Provide the patent applica	ation n	number(s):_				_
[IF YES] What is the nature of you  New drug  New use of drug  Medical product  Environmental co  New process or p  New research medical  New gene  Other please spe	or dev ontrols oroced ethod	ice and servic	es			

	lave you <b>com</b> patent(s)?	mercialized	your innovation based	on your
		☐ No		
[1	IF YES]	·=	units have you sold? ur total sales?	\$
	lave you <b>licen</b> ☑ Yes	sed your in ☐ No	novation(s)?	
	oid any <b>Federa</b> ☑ Yes	al agencies :	support this work?	
_	IF YES] <b>Which</b> Please check o		ral agencies supported y)	this work?
Ī	NIEHS			
	NHLBI			
	NIAID			
<del>-</del>	NICHD			
	Other NIH			
<del>-</del>	CDC		U	
7	AHRQ			
	FDA		U	
I	EPA		U	
Ī	HUD			
1	NSF			
(	Other US			
{	government (	not		
1	listed above)			
Have you spun-off or st selected science portfo  ☐ Yes ☐ No		<b>company</b> ba	sed on your research re	elated to the

# **Community Partnership Outputs**

Describe any community outreach outputs produced by your project, such as Outreach visits, interventions, curriculums, etc.:
Describe the target audience (include specific numbers of people reached if possible):
Describe the goal of the community partnership:
Describe the ways community partners participated in the project:
Describe any leadership roles community partners had in the project:

#### **IMPACTS**

We are interested in assessing whether you think your research will have effects on long term outcomes (now or in the near future) through a variety of pathways, including clinical practice changes, reduced exposure to environmental hazards, or changes in public behavior and advocacy. For each of the following items, please mark the 'current' box if you believe your research has already affected change in this area and the 'future potential' box if you believe it has the potential to affect change in the next 10 years.

lm	pact Area	Impact Timing
a.	My research has led to greater <b>understanding of</b> selected science portfolio <b>disease mechanisms</b>	□Current □Future potential
	Describe impact:	
b.	My research has led to greater understanding of individual, social, and environmental factors associated with selected science portfolio	□Current □Future potential
	Describe impact:	
c.	My research has led to improved <b>environmental measurement techniques</b>	☐Current ☐Future potential
	Describe impact:	
d.	My research has led to increased evidence regarding <b>effective interventions</b>	□Current □Future potential
	Describe impact:	
e.	My research has led to improved <b>environmental control techniques</b>	□Current □Future potential
	Describe impact:	
f.	My research has led to changes in <b>education outcomes for clinical/public health students</b>	□Current □Future potential
	Describe impact:	
g.	My research has led to changes in <b>education outcomes for K-12 or families</b>	□Current □Future potential
	Describe impact:	
h.	My research has led to changes in <b>business</b> practices regarding selected science portfolio	□Current □Future potential
	Describe impact:	
lm	pact Area	Impact Timing

i.	My research has led to changes in environmental standards or regulations for change to reflect selected science portfolio	□Current	☐Future potential
	Describe impact:		
j.	My research has led to changes in environmental policies for selected science portfolio	□Current	☐Future potential
	Describe impact:		
k.	My research has led to changes in <b>clinical practice</b> relevant to <b>selected science portfolio</b>	□Current	☐Future potential
	Describe impact:		
l.	My research has led to changes in <b>public knowledge and practices</b> related to <b>selected science portfolio</b> prevention and control	□Current	☐Future potential
	Describe impact:		
m.	My research has led to increased <b>public</b> advocacy for selected science portfolio prevention and control	□Current	☐Future potential
	Describe impact:		
n.	My research has led to changes in behavior related to the field of <u>selected science portfolio</u>	□Current	☐Future potential

## **SCIENTIFIC GOALS AND OBJECTIVES**

Describe the key scientific findings associated with your funded research.
Describe the impact or potential impact of these findings on public health.
Describe the impact or potential impact of these findings on the field of XXX.
How did any workshops or meetings related to the <u>selected science portfolio</u> affect your project goals?
Prior to the FOA in this area, were you already conducting research in the <u>selected</u> <u>science portfolio</u> ?
Describe any research objectives you were not able to achieve with the current budget allocated to this grant.
RFA Goals (if applicable)
The goals of the RFAs for this portfolio include: (list goals here.)
To what extent did your project address each of these goals?
Did the FOA encourage you to take your research in a new direction?
What obstacles are there in expanding this selected science portfolio?
Do you think a new FOA in the <u>selected science portfolio</u> could solicit research that would help overcome the obstacles you encountered?  Yes  No

If yes, share your thoughts on how a funding opportunity could help; including development of tools or standardized measurements that are lacking, etc.:

# Research Agenda

What <u>selected science portfolio</u> -related research topics would you like to see include among the NIEHS extramural research priorities over the next 5-10 years to address emerging science areas or areas where there are gaps in current research		
RESEARCH COLLABORATIONS		
Do/Did you collaborate with other grantees who are doing similar work? Yes/No		
If so, describe the collaboration:		
Is there a collaborator or partner that you would like to work with more? Yes/No		
If so, who and why?		
What has prevented you from pursuing that relationship?		
Is there anything NIEHS can do to help facilitate that relationship?		

#### **PROGRAM SUPPORT**

How satisfied are you with the support you received from program staff, such as grantee meetings, communications, etc.?

	Everything was Great	Mostly OK	So-So (3)	Could have been better	Provided little or no	Not Applicable
	(5)	(4)	(3)	(2)	help (1)	Арріісавіс
Grantee meetings						
Regular communication						
Workgroups						
Sharepoint sites or similar web-						
based sharing						
Webinars						
Data or sample sharing						
Methods or technologies						
Other activities provided based						
on program or portfolio selected						

What was the most beneficial type of support you received from program staff? And why?

Are there other support activities that NIEHS program staff could have provided that would have facilitated your research project? Yes/No

If yes, please describe:
lf yes, please describe:

#### **Grant Administration**

Was there a budget change during the grant period?

Did you have trouble finding staff resources for the research?

Was there a change in research aim(s)? If so, please provide details.

#### IF COLLABORATIVE OR CONSORTIUM TYPE FUNDING:

Describe your participation in the current consortium.

In addition to your individual grant accomplishments, what do you see as the main accomplishments of the consortium efforts? (both methods and findings)

[if history of funding from NIEHS] How does your experience with this consortium model differ from other grants you have been involved with at NIEHS?

What do you see as the primary benefits with funding this research through a consortium?

What are the primary challenges associated with funding this research through a consortium?

To what extent have joint products emerged from the consortium (e.g., joint publications, presentations, new collaborations, shared datasets, new grants?) What were the benefits and challenges involved in working on these joint products?

How satisfied are you with those efforts?

Do you anticipate continuing to collaborate with any of these consortium members after this grant is over? Please describe your plans.

**LESSONS LEARNED** (Note to OMB: this section will be customized for each portfolio or program evaluation to address unique characteristics of the portfolio or program, such as the funding mechanism used or partnering and collaboration requirements. Potential questions are provided below.)

Would you recommend that NIEHS use the consortium model in future funding announcements?

What (if anything) would you want to see done differently related to how the consortium was convened or managed?

Many grant programs today are specifically looking at research translation and the broader societal impacts of the use of research findings including informing regulation. Based on your experiences with this grant, what do you think is the best way to conduct research to translate findings to affect broader social impacts and/or to inform the regulatory process?

Are there any other lessons learned you would like to share regarding your participation in this grant?